GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Interest Coverage

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Coeptis Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $-2.92 Mil. Coeptis Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2024 was $-0.20 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Coeptis Therapeutics Holdings's Interest Coverage or its related term are showing as below:


COEP's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 145.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Coeptis Therapeutics Holdings Interest Coverage Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Coeptis Therapeutics Holdings Interest Coverage Chart

Coeptis Therapeutics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Coverage
- - - -

Coeptis Therapeutics Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Coeptis Therapeutics Holdings's Interest Coverage

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coeptis Therapeutics Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's Interest Coverage falls into.



Coeptis Therapeutics Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Coeptis Therapeutics Holdings's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Coeptis Therapeutics Holdings's Interest Expense was $-0.11 Mil. Its Operating Income was $-21.49 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.21 Mil.

Coeptis Therapeutics Holdings did not have earnings to cover the interest expense.

Coeptis Therapeutics Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Coeptis Therapeutics Holdings's Interest Expense was $-0.20 Mil. Its Operating Income was $-2.92 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.21 Mil.

Coeptis Therapeutics Holdings did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Coeptis Therapeutics Holdings  (NAS:COEP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Coeptis Therapeutics Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Executives
Tara Desilva director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick director, 10 percent owner, officer: CEO and President 5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran director 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind director 1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace director, officer: VP of Operations 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise director, 10 percent owner, officer: Chief Financial Officer 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps director 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy officer: CFO and Secretary 206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc 10 percent owner 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc 10 percent owner 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr. 10 percent owner 151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp 10 percent owner 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019